RxDoctor Payments Data

Kent Kirk, MD

Ophthalmology · River Forest, ILNPI 1154340941

Payments from drug & device makers

$3,644in general payments, 2019–2025

Across 78 payments — averaging $46.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microsurgical Technology, Inc.$1K
  • Johnson & Johnson Surgical Vision, Inc.$491
  • Rxsight Inc$460
  • Alcon$415
  • Bausch & Lomb Americas Inc.$156
  • Novartis$132
  • plus $857 from 19 others

What the payments were for

  • Speaking & faculty fees$321%
  • Food & beverage$2,47968%
  • Charitable contribution$1,13331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,644 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$343,075
Medicare patients
1,172
Services billed
2,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$44,363
LumiganBimatoprost50$23,117
CombiganBrimonidine Tartrate/Timolol38$14,873
XiidraLifitegrast14$14,584
Latanoprost469$7,427
Brinzolamide25$4,900
Brimonidine Tartrate54$4,666
Prednisolone Acetate58$3,386
VyzultaLatanoprostene Bunod12$2,986
Travoprost19$2,811
SimbrinzaBrinzolamide/Brimonidine Tart13$2,691
Timolol Maleate112$2,219
Ketorolac Tromethamine44$1,028
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat72$1,014
Dorzolamide Hcl27$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$76$82,353121 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$156$17,57126 claims
AlconSimbrinza$415$2,69113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in River Forest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →